GSA Capital Partners’s Lifecore Biomedical LFCR Stock Holding History

GSA Capital Partners’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$462K	Sell	88,052 -37,698	-30%	-$190K	0.03%	1054
2026 Q1	$468K	Buy	125,750 +42,956	+52%	+$297K	0.03%	962
2025 Q4	$677K	Buy	+82,794	New	+$612K	0.06%	617
2023 Q1	–	Sell	-19,966	Closed	-$129K	–	1719
2022 Q4	$129K	Buy	19,966 +4,556	+30%	+$37.5K	0.02%	1276
2022 Q3	$137K	Buy	+15,410	New	+$157K	0.02%	1313
2021 Q4	–	Sell	-40,153	Closed	-$370K	–	1624
2021 Q3	$370K	Buy	+40,153	New	+$437K	0.04%	884
2021 Q1	–	Sell	-23,606	Closed	-$256K	–	1301
2020 Q4	$256K	Sell	23,606 -24,333	-51%	-$251K	0.04%	828
2020 Q3	$466K	Buy	47,939 +33,335	+228%	+$317K	0.08%	439
2020 Q2	$116K	Buy	+14,604	New	+$151K	0.06%	456
2019 Q3	–	Sell	-13,129	Closed	-$123K	–	1561
2019 Q2	$123K	Buy	+13,129	New	+$133K	0.01%	1321

Other funds holding LFCR

Wynnefield Capital New York $145M AUM 14.57% 1-Year Est. Return

LPAM

Legion Partners Asset Management Los Angeles, California $40.6M AUM 156.55% 1-Year Est. Return

GRIM

Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return

325 Capital New York $419M AUM 75.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

QOP

Quinn Opportunity Partners Charlottesville, Virginia $2.16B AUM 28.56% 1-Year Est. Return

GSA Capital Partners's LFCR Position: Q2 2026 in Review

GSA Capital Partners reduced its Lifecore Biomedical (LFCR) stake by 30% in Q2 2026, selling an estimated $190K and leaving 88,052 shares worth $462K. The position accounts for 0.03% of the portfolio, ranked #1054.

GSA Capital Partners first reported a position in LFCR in Q2 2019 and has held it in 10 quarters since. The position peaked at $677K in Q4 2025. 99 funds tracked by Wall St. Rank hold LFCR as of Q2 2026.

GSA Capital Partners held 88,052 shares of Lifecore Biomedical worth $462K as of Q2 2026.
GSA Capital Partners sold 37,698 Lifecore Biomedical shares in Q2 2026, an estimated $190K.
Lifecore Biomedical made up 0.03% of GSA Capital Partners's portfolio in Q2 2026, its #1054 holding.
GSA Capital Partners first reported a position in Lifecore Biomedical in Q2 2019 and has held it in 10 quarters since.
GSA Capital Partners's Lifecore Biomedical position peaked at $677K in Q4 2025.
99 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.